Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
17.14
+1.24 (7.80%)
At close: Jan 16, 2026, 4:00 PM EST
16.98
-0.16 (-0.93%)
After-hours: Jan 16, 2026, 7:50 PM EST
TNXP Revenue
Tonix Pharmaceuticals Holding had revenue of $3.29M in the quarter ending September 30, 2025, with 16.58% growth. This brings the company's revenue in the last twelve months to $10.30M, down -8.79% year-over-year. In the year 2024, Tonix Pharmaceuticals Holding had annual revenue of $10.09M with 29.94% growth.
Revenue (ttm)
$10.30M
Revenue Growth
-8.79%
P/S Ratio
10.18
Revenue / Employee
$127,148
Employees
81
Market Cap
212.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.09M | 2.33M | 29.94% |
| Dec 31, 2023 | 7.77M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TNXP News
- 12 days ago - Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026 - GlobeNewsWire
- 20 days ago - Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering - GlobeNewsWire
- 20 days ago - Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) - GlobeNewsWire
- 4 weeks ago - Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel - GlobeNewsWire
- 7 weeks ago - Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications - Seeking Alpha
- 7 weeks ago - Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder - GlobeNewsWire
- 2 months ago - Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment - GlobeNewsWire